Verona Pharma plc
veronapharma.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2025 10-Q, filed Aug 6, 2025. Its latest SEC filing is a EFFECT from Nov 14, 2025.
10-Q for Q2 FY2025, filed Aug 6, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops and sells Ohtuvayre, an inhaled treatment for chronic obstructive pulmonary disease, and develops other respiratory therapies for patients with COPD, asthma, cystic fibrosis and bronchiectasis.
10-K for FY2024, filed Feb 27, 2025We are a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory…View ↗
On June 26, 2024, the U.S. Food and Drug Administration (“FDA”) approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic…View ↗
In Phase 2 clinical trials, ensifentrine has demonstrated positive results in patients with COPD, asthma and cystic fibrosis (“CF”). Two…View ↗
Based on the clinical results of ensifentrine observed in patients with COPD, including improvements in lung function and symptoms of cough…View ↗
How Did They Make Money?
Specialty pharmacies buy Ohtuvayre, and the company is paid when the pharmacies receive delivered product. It can also receive milestone payments and royalties from its Greater China license.
10-K for FY2024, filed Feb 27, 2025
$42.3M
-
10-K for FY2024, filed Feb 27, 2025
$42.3M ↗
Who Were Their Customers?
Specialty pharmacies buy Ohtuvayre from the company and resell it to patients and health care providers. Nuance Pharma has exclusive rights to develop and commercialize ensifentrine in Greater China.
10-K for FY2024, filed Feb 27, 2025
10-K for FY2024, filed Feb 27, 2025
For the year ended December 31, 2024 the Company relied on four specialty pharmacies to purchase and supply Ohtuvayre to patients. These…View ↗
Did Revenues Turn Into Profits?
No. It lost $173.4M in FY2024.
10-K for FY2024, filed Feb 27, 2025
−$154.6MView ↗
10-K for FY2024, filed Feb 27, 2025
−$173.4MView ↗
10-K for FY2024, filed Feb 27, 2025
−$122.8MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2025, filed Aug 6, 2025
$11.9MView ↗
- ▲ Now profitable
- vs −$70.8M in Q2 FY2024
-
Oct 7, 2025
Merck completed its acquisition of Verona Pharma
Verona became an indirect wholly owned subsidiary of Merck, and its ADSs were delisted from Nasdaq.
Sources
8-K, filed Oct 7, 2025
On October 6, 2025, the High Court of Justice of England and Wales (the “Court”) sanctioned the Scheme of Arrangement at a public hearing…View ↗
-
Jul 9, 2025
Verona agreed to be acquired by Merck
Merck, through a subsidiary, agreed to acquire Verona for $107 per ADS in cash.
Sources
8-K, filed Jul 9, 2025
Under the Transaction Agreement, at the effective time of the Scheme of Arrangement (the “Effective Time”), all ordinary shares, nominal…View ↗
From clinical development to commercialization
The older report described Verona as a clinical-stage company developing ensifentrine and planning a future U.S. launch. The latest report describes Ohtuvayre as an approved and launched product being sold in the U.S., alongside continued development of other respiratory treatments.
10-K for FY2021, filed Mar 3, 2022 10-K for FY2024, filed Feb 27, 2025We are a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory…View ↗
On June 26, 2024, the U.S. Food and Drug Administration (“FDA”) approved Ohtuvayre (ensifentrine) for the maintenance treatment of chronic…View ↗
We are commercializing Ohtuvayre for the maintenance treatment of COPD in the U.S. Outside the U.S., we intend to license Ohtuvayre to…View ↗
Who Did They Compete With?
Competes with AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Chiesi, and Sanofi
10-K for FY2024, filed Feb 27, 2025In the DPI/pMDI maintenance treatment of COPD market, ensifentrine’s current closest potential competitors are Symbicort®, a combination of…View ↗
Loading...
